This finding aligns with previous reports indicating that stromal cells have a lower mutation burden, and a more stable genome compared to cancer cells.[25] In summary, our findings demonstrate that pericyte‐IL32 expression may determine the patient prognosis in EGFR‐mutated NSCLC patients and warrant further functional studies. This evidence concerns the gene IL32 and cancer.